BIO-RAD LABORATORIES-A (BIO) Fundamental Analysis & Valuation
NYSE:BIO • US0905722072
267.83 USD
-3.61 (-1.33%)
Last: Mar 10, 2026, 03:59 PM
This BIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
Taking everything into account, BIO scores 5 out of 10 in our fundamental rating. BIO was compared to 57 industry peers in the Life Sciences Tools & Services industry. BIO is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. BIO is quite expensive at the moment. It does show a decent growth rate.
1. BIO Profitability Analysis
1.1 Basic Checks
- In the past year BIO was profitable.
- In the past year BIO had a positive cash flow from operations.
- In multiple years BIO reported negative net income over the last 5 years.
- In the past 5 years BIO always reported a positive cash flow from operatings.
1.2 Ratios
- With an excellent Return On Assets value of 7.18%, BIO belongs to the best of the industry, outperforming 84.21% of the companies in the same industry.
- With a decent Return On Equity value of 10.20%, BIO is doing good in the industry, outperforming 78.95% of the companies in the same industry.
- BIO's Return On Invested Capital of 2.02% is fine compared to the rest of the industry. BIO outperforms 61.40% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for BIO is significantly below the industry average of 11.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.18% | ||
| ROE | 10.2% | ||
| ROIC | 2.02% |
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
1.3 Margins
- The Profit Margin of BIO (29.42%) is better than 96.49% of its industry peers.
- In the last couple of years the Profit Margin of BIO has declined.
- BIO's Operating Margin of 10.30% is fine compared to the rest of the industry. BIO outperforms 70.18% of its industry peers.
- In the last couple of years the Operating Margin of BIO has declined.
- With a decent Gross Margin value of 52.01%, BIO is doing good in the industry, outperforming 61.40% of the companies in the same industry.
- In the last couple of years the Gross Margin of BIO has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.3% | ||
| PM (TTM) | 29.42% | ||
| GM | 52.01% |
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
2. BIO Health Analysis
2.1 Basic Checks
- BIO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- BIO has less shares outstanding than it did 1 year ago.
- The number of shares outstanding for BIO has been reduced compared to 5 years ago.
- The debt/assets ratio for BIO has been reduced compared to a year ago.
2.2 Solvency
- BIO has an Altman-Z score of 3.09. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of BIO (3.09) is better than 66.67% of its industry peers.
- The Debt to FCF ratio of BIO is 3.21, which is a good value as it means it would take BIO, 3.21 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of BIO (3.21) is better than 82.46% of its industry peers.
- A Debt/Equity ratio of 0.16 indicates that BIO is not too dependend on debt financing.
- BIO has a Debt to Equity ratio of 0.16. This is comparable to the rest of the industry: BIO outperforms 56.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 3.21 | ||
| Altman-Z | 3.09 |
ROIC/WACC0.19
WACC10.45%
2.3 Liquidity
- A Current Ratio of 5.62 indicates that BIO has no problem at all paying its short term obligations.
- BIO's Current ratio of 5.62 is amongst the best of the industry. BIO outperforms 82.46% of its industry peers.
- A Quick Ratio of 4.19 indicates that BIO has no problem at all paying its short term obligations.
- BIO has a better Quick ratio (4.19) than 75.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.62 | ||
| Quick Ratio | 4.19 |
3. BIO Growth Analysis
3.1 Past
- BIO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.78%.
- BIO shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.19% yearly.
- The Revenue has been growing slightly by 0.65% in the past year.
- Measured over the past years, BIO shows a small growth in Revenue. The Revenue has been growing by 0.29% on average per year.
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%
3.2 Future
- Based on estimates for the next years, BIO will show a small growth in Earnings Per Share. The EPS will grow by 0.58% on average per year.
- BIO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.54% yearly.
EPS Next Y4.57%
EPS Next 2Y7.58%
EPS Next 3Y7.11%
EPS Next 5Y0.58%
Revenue Next Year1.81%
Revenue Next 2Y2.49%
Revenue Next 3Y2.54%
Revenue Next 5Y2.54%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. BIO Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 27.00 indicates a quite expensive valuation of BIO.
- 66.67% of the companies in the same industry are more expensive than BIO, based on the Price/Earnings ratio.
- When comparing the Price/Earnings ratio of BIO to the average of the S&P500 Index (26.45), we can say BIO is valued inline with the index average.
- BIO is valuated quite expensively with a Price/Forward Earnings ratio of 25.82.
- BIO's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BIO is cheaper than 66.67% of the companies in the same industry.
- BIO's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.65.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27 | ||
| Fwd PE | 25.82 |
4.2 Price Multiples
- BIO's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BIO is cheaper than 84.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.3 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)5.91
PEG (5Y)N/A
EPS Next 2Y7.58%
EPS Next 3Y7.11%
5. BIO Dividend Analysis
5.1 Amount
- BIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BIO Fundamentals: All Metrics, Ratios and Statistics
NYSE:BIO (3/10/2026, 3:59:05 PM)
267.83
-3.61 (-1.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12 2026-02-12/amc
Earnings (Next)04-29 2026-04-29/amc
Inst Owners90.44%
Inst Owner Change-2.09%
Ins Owners8.17%
Ins Owner Change0%
Market Cap7.23B
Revenue(TTM)2.58B
Net Income(TTM)759.90M
Analysts76
Price Target341.7 (27.58%)
Short Float %5.19%
Short Ratio3.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.88%
Min EPS beat(2)-7.97%
Max EPS beat(2)15.74%
EPS beat(4)3
Avg EPS beat(4)23.95%
Min EPS beat(4)-7.97%
Max EPS beat(4)49.07%
EPS beat(8)7
Avg EPS beat(8)28.31%
EPS beat(12)9
Avg EPS beat(12)18.55%
EPS beat(16)11
Avg EPS beat(16)17.09%
Revenue beat(2)0
Avg Revenue beat(2)-0.54%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)-0.35%
Revenue beat(4)2
Avg Revenue beat(4)1.22%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)0.02%
Revenue beat(12)3
Avg Revenue beat(12)-1.41%
Revenue beat(16)5
Avg Revenue beat(16)-1.09%
PT rev (1m)-5.63%
PT rev (3m)-5.63%
EPS NQ rev (1m)-20.96%
EPS NQ rev (3m)-21.27%
EPS NY rev (1m)1.2%
EPS NY rev (3m)-0.1%
Revenue NQ rev (1m)-2.46%
Revenue NQ rev (3m)-2.59%
Revenue NY rev (1m)-0.56%
Revenue NY rev (3m)-0.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27 | ||
| Fwd PE | 25.82 | ||
| P/S | 2.8 | ||
| P/FCF | 19.3 | ||
| P/OCF | 13.58 | ||
| P/B | 0.97 | ||
| P/tB | 1.08 | ||
| EV/EBITDA | N/A |
EPS(TTM)9.92
EY3.7%
EPS(NY)10.37
Fwd EY3.87%
FCF(TTM)13.88
FCFY5.18%
OCF(TTM)19.72
OCFY7.36%
SpS95.71
BVpS276.16
TBVpS248.22
PEG (NY)5.91
PEG (5Y)N/A
Graham Number248.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.18% | ||
| ROE | 10.2% | ||
| ROCE | 2.65% | ||
| ROIC | 2.02% | ||
| ROICexc | 2.38% | ||
| ROICexgc | 2.62% | ||
| OM | 10.3% | ||
| PM (TTM) | 29.42% | ||
| GM | 52.01% | ||
| FCFM | 14.5% |
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
ROICexc(3y)2.76%
ROICexc(5y)2.85%
ROICexgc(3y)3.02%
ROICexgc(5y)3.08%
ROCE(3y)3.04%
ROCE(5y)3.23%
ROICexgc growth 3Y-9.86%
ROICexgc growth 5Y-2.45%
ROICexc growth 3Y-10.58%
ROICexc growth 5Y-3.39%
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
F-Score5
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 3.21 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.1% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 49.3% | ||
| Current Ratio | 5.62 | ||
| Quick Ratio | 4.19 | ||
| Altman-Z | 3.09 |
F-Score5
WACC10.45%
ROIC/WACC0.19
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)6.44%
Cap/Sales(5y)5.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
EPS Next Y4.57%
EPS Next 2Y7.58%
EPS Next 3Y7.11%
EPS Next 5Y0.58%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%
Revenue Next Year1.81%
Revenue Next 2Y2.49%
Revenue Next 3Y2.54%
Revenue Next 5Y2.54%
EBIT growth 1Y-12.48%
EBIT growth 3Y-18.24%
EBIT growth 5Y-8.78%
EBIT Next Year46.85%
EBIT Next 3Y17.21%
EBIT Next 5Y9.79%
FCF growth 1Y40.72%
FCF growth 3Y66.2%
FCF growth 5Y-4.69%
OCF growth 1Y16.92%
OCF growth 3Y39.89%
OCF growth 5Y-1.87%
BIO-RAD LABORATORIES-A / BIO FAQ
What is the fundamental rating for BIO stock?
ChartMill assigns a fundamental rating of 5 / 10 to BIO.
Can you provide the valuation status for BIO-RAD LABORATORIES-A?
ChartMill assigns a valuation rating of 4 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Fairly Valued.
What is the profitability of BIO stock?
BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 6 / 10.
Can you provide the expected EPS growth for BIO stock?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to grow by 4.57% in the next year.